Botulinum Toxin MarketSize and Trends

Botulinum Toxin Market: Drivers

Frequent approvals of novel botulinum toxin products for different indications are expected to drive growth of the Botulinum toxin market in near future. For instance, in 2016, Ipsen S.A. received the U.S. Food and Drug Administration (FDA) approval for its Dysport (abobotulinumtoxinA) injection indicated for the treatment of pediatric lower limb (PLL) spasticity in children of age two years and older. In 2017, company received the FDA approval for same product to use in adults. In 2017, Allergan plc. received FDA approval for BOTOX Cosmetic (OnabotulinumtoxinA) for new indication in forehead lines, and previously the product has been approved for the treatment of , crow's feet lines, and glabellar lines. With this approval company has expanded the indication of its product in the temporary improvement in the appearance of moderate to severe forehead lines associated with frontalis muscle activity in adults. In 2014, Allergan Inc. received approval for its BOTOX (Botulinum toxin type A) from Medicines and Healthcare Products Regulatory Agency (MHRA) in U.K. BOTOX was approved in the U.K. for treatment of ankle disability due to lower limb spasticity associated with stroke in adults. In 2016, Daewoong Pharmaceutical Co., Ltd received approval for its botulinum toxin Nabota in Mexico and India. Nabota was introduced by Daewoong Pharmaceutical Co., Ltd in South Korea in 2014. In 2015, Merz North America, the U.S. subsidiary of the global Merz Pharma Group, received U.S. FDA approval for Xeomin (incobotulinumtoxinA) indicated for the treatment of upper limb spasticity (ULS) in adult patients. Furthermore, increasing trend of botulinum toxin in cosmetic procedures is also expected to increase the growth of botulinum toxin market in near future. For instance, according to a report published by American Society of Plastic Surgeons in 2016, around 7,056,255 cosmetic minimally-invasive procedures were performed with Botulinum toxin Type A (Botox, Dysport, and Xeomin), there was an increase of 4% in procedures as compared to 2015. Increasing number of procedures with botulinum toxin along with increasing approved indication is expected to drive growth of the global botulinum toxin market.

Botulinum Toxin Market: Market Taxonomy

The global botulinum toxin market has been segmented based on product type, application, distribution channel, and geography: